Pharmacological and genetic characterisation of the canine P2X4 receptor by Sophocleous, Reece A. et al.
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/bph.15009 
 
This article is protected by copyright. All rights reserved. 
Sophocleous Reece A (Orcid ID: 0000-0002-8339-9090) 
Finol-Urdaneta Rocio K. (Orcid ID: 0000-0003-2157-4532) 
 
 
Pharmacological and genetic characterisation of the canine P2X4 receptor 
 
Running title: The canine P2X4 receptor 
 
Reece A. Sophocleous1,2, Tracey Berg1,2, Rocio K. Finol-Urdaneta1,3, Vanessa Sluyter1,2, 
Shikara Keshiya1,2, Lachlan Bell1,2, Stephen J. Curtis4, Belinda L. Curtis4, Aine Seavers5, 
Rachael Bartlett1,2, Mark Dowton1,2, Leanne Stokes6, Lezanne Ooi1,2 and Ronald Sluyter1,2 
 
1Illawarra Health and Medical Research Institute, Wollongong, NSW 2522, Australia; 
2Molecular Horizons and School of Chemistry and Molecular Bioscience, University of 
Wollongong, Wollongong, NSW 2522, Australia; 3Electrophysiology Facility for Cell 
Phenotyping and Drug Discovery, Wollongong, NSW 2522, Australia; 4Albion Park 
Veterinary Hospital, Albion Park, NSW 2527, Australia; 5Oak Flats Veterinary Clinic, Oak 
Flats, NSW 2529, Australia; 6School of Pharmacy, University of East Anglia, Norwich NR4 
7TJ, United Kingdom. 
 
Word Count (excluding abstract, methods, references and figure legends)  





This article is protected by copyright. All rights reserved. 
Acknowledgments 
This work was supported by the American Kennel Club Canine Health Foundation (Grant 
01985). R.A.S. was supported through an Australian Government Research Training Program 
Scholarship. L.O. is supported by a National Health and Medical Research Council 
(NHMRC) of Australia Boosting Dementia Research Leadership Fellowship (APP1135720). 
We thank Margaret Phillips (University of Wollongong) and staff of the Illawarra Health and 
Medical Research Institute for technical assistance. We thank Professor Heath Ecroyd 
(University of Wollongong) for advice. 
 
Ethics Statement 
Informed consent was obtained from all pet owners. This work was approved by the Animal 
(protocols AE10/01 and AE14/09) and Human (protocol HE10/063) Ethics Committees of 
the University of Wollongong. 
 
Conflict of Interest 
The authors declare no conflict of interest. 
 
Address for Correspondence 
Professor Ronald Sluyter, School of Chemistry and Molecular Bioscience, University of 






This article is protected by copyright. All rights reserved. 
Abstract 
Background and Purpose 
The P2X4 receptor is an emerging therapeutic target for the treatment of chronic pain and 
cardiovascular disease. Dogs are well-recognised natural models of human disease but 
information regarding P2X4 in dogs is absent. To aid the development and validation of 
P2X4-targeting therapeutics, this study aimed to characterise and compare canine and human 
P2X4. 
Experimental Approach 
Genomic DNA was extracted from whole blood samples from 101 randomly selected dogs 
and sequenced across the P2RX4 gene to identify potential missense variants. Recombinant 
canine and human P2X4 tagged with Emerald GFP were expressed in 1321N1 and HEK293 
cells and analysed by immunoblotting and confocal microscopy. P2X4 pharmacology was 
characterised using nucleotide-induced Fura-2 AM measurements of intracellular Ca2+ 
responses and known P2X4 antagonists in 1321N1 and HEK293 cells. P2X4-mediated 
inward currents in HEK293 cells were assessed by automated patch clamp.  
Key Results 
No P2RX4 missense variants were identified in any canine samples. Canine and human P2X4 
were localised primarily to lysosomal compartments. ATP was identified as the primary 
agonist of canine P2X4 with near identical efficacy and potency at human P2X4. 2’(3’)-O-(4-
benzoyl)benzoyl ATP (BzATP), but not ADP, was identified as a partial agonist with reduced 
potency for dog P2X4 compared to the human orthologue. Five antagonists inhibited canine 
P2X4, with BX430 displaying reduced sensitivity and potency against canine P2X4.  
Conclusion and Implications 
P2X4 is highly conserved across dog pedigrees and displays a similar expression pattern and 
pharmacological profile to human P2X4, providing support for validation and use of 
therapeutics designed for P2X4-related disease onset and management in dogs and humans. 
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Abbreviations: 5-BDBD, 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-
diazepin-2-one; BX430, (1-(2,6-dibromo-4-isopropyl-phenyl)-3-(3-pyriudyl)urea; BzATP, 2′- 
& 3′-O-(4benzoylbenzoyl) ATP; ECS, extracellular Ca2+ solution; EmGFP, Emerald green 
fluorescent protein HRP, horseradish peroxidase; IVM, ivermectin; TNP-ATP, 2’,3’-O-
(2,4,6-trinitrophenyl) ATP. 
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Bullet point summary 
What is already known 
 P2X4 is expressed in humans and rodents with known roles in nociception and 
cardiovascular regulation. 
 No data regarding functional canine P2X4 has been reported. 
What this study adds 
 Canine P2RX4 encodes a functional ATP-gated Ca2+ channel with pharmacological 
similarities to human P2X4. 
 The P2X4-selective inhibitor BX430 is less potent and sensitive against canine 
compared to human P2X4. 
Clinical significance 
 Compounds targeting human P2X4 also target canine P2X4 with similar 
effectiveness. 
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Introduction 
P2X4 is a member of the ionotropic P2X receptors and forms homo-trimeric, ATP-gated Ca2+ 
channels in macrophages and glial cells (Trang & Salter, 2012; Tsuda, Tozaki-Saitoh et al., 
2010). Here it has important roles in signalling the release of prostaglandin E2 (Ulmann, 
Hirbec et al., 2010) and brain-derived neurotrophic factor (Trang, Beggs et al., 2009; 
Ulmann, Hatcher et al., 2008), respectively. Elucidation of the role of P2X4 in these well-
known nociceptive signalling pathways has led to suggestions that P2X4 is an attractive 
therapeutic target for the treatment of a number of major health issues such as inflammation 
and chronic pain (Bernier, Ase et al., 2018), nerve injuries (Su, Wu et al., 2019) and alcohol 
use disorder (Huynh, Arabian et al., 2016). Functional P2X4 is also present on endothelial 
cells in humans and mice where it is associated with blood flow-dependent calcium signalling 
(Yamamoto, Korenaga et al., 2000; Yamamoto, Sokabe et al., 2006).  
To date, two different missense variants in the gene coding P2X4 (P2RX4) have been 
associated with human disease. The missense Y315C variant (rs28360472) is significantly 
associated with increased pulse pressure (Stokes, Scurrah et al., 2011). The same variant is 
associated with increased susceptibility to age-related macular degeneration when in linkage 
disequilibrium with a P2RX7 missense G150R variant (rs28360447), which results in a 
reduction of P2X7-mediated phagocytosis by macrophages and microglia (Gu, Baird et al., 
2013). A second P2RX4 variant (G135S; rs765866317) in a three-variant haplotype (together 
with the P2RX7 variants T205M; rs140915863 and N361S; rs201921967) is associated with 
multiple sclerosis in a multi-incident family (Sadovnick, Gu et al., 2017). As such, P2X4 has 
been proposed as a possible therapeutic target for the treatment of multiple sclerosis (Zabala, 
Vazquez‐Villoldo et al., 2018). 
Despite the publication of high resolution crystal structures of zebrafish P2X4 (Hattori & 
Gouaux, 2012; Kawate, Michel et al., 2009), researchers have struggled to identify potent and 
selective P2X4 antagonists (Tian, Abdelrahman et al., 2014). However, in recent years, 
several commercially available antagonists with greater selectivity for P2X4 have appeared, 
although with disputed effectiveness. Data regarding P2X sub-type specificity and species-
selectivity is incomplete (See Stokes, Layhadi et al., 2017 for a review of current P2X4 
antagonists). Overcoming species-specific pharmacological differences is a huge challenge 
faced by researchers developing drugs that target ion channels such as P2X4. Such 
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differences often hinder the translation of observations from pre-clinical animal models to 
humans. However, to date, the characterisation of canine P2X4 has not been reported.  
To assist with pre-clinical validation of therapeutics for P2X4-related disease, canine P2X4 
was synthesised and sub-cloned into a mammalian expression vector for functional 
characterisation, revealing a striking pharmacological similarity to human P2X4. Recently 
described human P2X4 antagonists were further characterised and their ability to inhibit Ca2+ 
flux through canine and human P2X4 was directly compared. 
 
Methods 
Genomic DNA isolation and sequencing 
Canine peripheral blood was collected into VACUETTE lithium heparin tubes (Greiner Bio-
One, Frickenheisen, Germany) from pedigree and non-pedigree dogs and studied in 
compliance with institutional (University of Wollongong) and ARRIVE guidelines. Genomic 
DNA was extracted from canine peripheral blood using the Wizard Genomic DNA 
Purification Kit (Promega, Madison, USA) according to manufacturer’s instructions and 
stored at -80°C. Canine genomic DNA was amplified using forward and reverse primer pairs 
designed to intronic regions flanking between one and three exons of canine P2RX4 as 
indicated (Supporting Table 1). PCR amplification was carried out using MangoTaq DNA 
polymerase with an initial denaturation at 95°C for 2 min, followed by 35-40 cycles of 
denaturation at 95°C for 30 s, annealing at 58.8-67°C for 30-60 s, and extension at 72°C for 1 
min. After cycling was complete, a final extension was carried out at 72°C for 5 minutes then 
amplicons were incubated with ExoSAP-IT at 37oC for 15 minutes, followed by heat 
inactivation at 80oC for 15 minutes. P2RX4 sequences from amplicons were determined using 
the respective primers listed in Supporting Table 1, the Applied Biosystems (Foster City, 
USA) ABI PRISM BigDye Terminator v3.1 Cycle Sequencing Kit and a 3130xl Genetic 
Analyser. Resulting sequence chromatograms were compared to the ENSEMBL reference 
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Expression constructs 
Synthetic canine and human P2RX4 cloned into pUC57 plasmids were purchased from 
Sigma-Aldrich (St Louis, USA) and sub-cloned into a mammalian pEGFP-N3 vector with a 
C-terminal Emerald green fluorescent (EmGFP) tag connected by a 3x (-GGGGS-) flexible 
linker. Plasmid DNA was amplified by transformation into chemically competent DH5α 
(Thermo Fisher Scientific, Melbourne, Australia) bacterial cells and isolated using the 
Wizard Plus SV Minipreps DNA Purification kit (Promega, Madison, USA) according to 
manufacturer’s instructions. Plasmid DNA was sequenced as above using primer pairs listed 
in Supporting Table 1. The canine and human P2RX4 sequences obtained from these vectors 
were identical to their respective full length reference transcripts obtained from ENSEMBL 




1321N1 human astrocytoma (ECACC Cat# 86030402, RRID:CVCL_0110) and HEK293 
cells (ECACC Cat# 85120602, RRID:CVCL_0045) were maintained in DMEM/F12 medium 
containing 15% or 10% FBS, respectively, 2 mM GlutaMAX, 100 U mL-1 penicillin, 10 
µg.mL-1 streptomycin and 1% non-essential amino acids at 37°C/5% CO2. Human cell line 
identities were confirmed through STR profiling (Garvan Molecular Genetics, Darlinghurst, 
Australia), and were routinely assessed for mycoplasma contamination using the MycoAlert 
Mycoplasma Detection Kit (Lonza, Waverley, Australia). Cells were plated at 3.5 x 105 cells 
per well in poly-D-lysine-coated 6-well plates (Greiner Bio-One, Frickenheisen, Germany) 
and transiently transfected the following day with canine or human P2X4-EmGFP, or the 
EmGFP empty vector (Sigma-Aldrich, St Louis, USA) using Lipofectamine3000 as per the 
manufacturer’s instructions. Briefly, 0.4 µg of plasmid DNA, 5 µL of Lipofectamine reagent, 
4 µL P3000 reagent and 250 µL Opti-MEM (per well of a 6-well plate transfection) were 
incubated at room temperature for 15 minutes prior to adding to cells. Post-transfection (24-
48 h), cells were plated at 5 x 104 cells per well in black-walled µClear bottom, poly-D-
lysine-coated 96-well plates (Greiner Bio-One) for Ca2+ flux assays, or at 1 x 105 cells per 18 
mm poly-D-lysine-coated glass coverslip for confocal microscopy, and incubated at 37°C/5% 
CO2 overnight . 
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Fura-2 calcium response assay 
P2X4 activity was assessed using Fura-2 measurements of nucleotide-induced Ca2+ influx as 
described (Ma, Hui et al., 2009). Unless stated otherwise, all assays and compound dilutions 
were carried out using a standard extracellular Ca2+ solution (ECS; 145 mM NaCl, 2 mM 
CaCl2, 1 mM MgCl2, 5 mM KCl, 13 mM glucose and 10 mM HEPES, pH 7.4). Cells were 
washed twice with ECS then pre-incubated with Fura-2 AM loading buffer (2.5 µM Fura-2 
AM/0.2% pluronic acid in ECS) in the dark for 30 minutes at 37°C. Before recording 
fluorescence, excess Fura-2 loading buffer was removed and cells were washed with ECS 
then incubated for a further 20 minutes to allow for complete de-esterification. Fura-2 
fluorescence emission at 510 nm was recorded every five seconds using a Flexstation3 
(Molecular Devices, Sunnyvale, USA) following excitation at 340 and 380 nm (six reads per 
well, photomultiplier tube setting medium). Baseline recordings were taken for 15 seconds 
then following the addition of nucleotide or vehicle (up to a final volume of 100 µL per well), 
recordings were taken for up to three minutes. Where indicated, antagonists, ivermectin 
(IVM) or respective vehicle controls were added to each column of the 96-well assay plate at 
regularly-spaced two-minute intervals at 37°C. After 20 minutes of pre-incubation, Fura-2 
fluorescence (as described above) was measured for 15 seconds then following the addition 
of ATP or vehicle (up to a final volume of 100 µL per well), recordings were taken for up to 
two minutes. Compound additions were carried out using the Flexstation3 built-in fluidics 
system. In some experiments, hexokinase (4.5 U.mL-1) was incubated with 1.5 mM ADP (or 
ATP) in ECS for 60 minutes at 37°C prior to addition of nucleotides. Data were acquired 
using SoftMax Pro 7 software (Molecular Devices). 
 
Automatic Planar Patch-Clamp Electrophysiology 
HEK293 cells transfected with canine or human P2X4 were detached from 6-well plates 
using TrypLE and resuspended in cold external recording solution (140 mM NaCl, 5 mM 
Glucose, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2 and 10 mM HEPES, 298 ± 3 mOsm, pH 7.4 
with NaOH) containing 1 U/mL apyrase. Cells were kept in suspension by automatic 
pipetting at 4°C. Patch-clamp measurements were performed on an NPC-16 Patchliner 
(Nanion Technologies, Munich, Germany) using multi-hole medium resistance NPC-16 chips 
with an average resistance of 1.1 MΩ. Recordings were made in the whole-cell configuration 
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with internal solution (60 mM CsF, 50 mM CsCl, 20 mM NaCl, 10 mM HEPES and 10 mM 
EGTA, 285 ± 3 mOsm, pH 7.2 with CsOH) and external recording solution in absence of 
apyrase. Seal formation was enhanced by brief treatment with SE seal enhancement solution 
(80 mM NaCl, 3 mM KCl, 10 mM MgCl2, 35 mM CaCl2 and 10 mM HEPES, 298 ± 3 
mOsm, pH 7.3 with NaOH) until stable seals were obtained and replaced with standard 
external solution. Solutions were 0.2-μm membrane filtered. Recordings where seal 
resistance (SR) was >500MΩ and access resistance was <3xSR were considered acceptable.  
Chip and whole-cell capacitance were fully compensated, and series resistance compensation 
(70%) was applied via Auto Rs Comp function. Recordings were acquired with PatchMaster 
(HEKA Elektronik, Lambrecht/Pfalz, Germany) and stored on a computer running 
PatchControlHT software (Nanion Technologies GmbH, Munich, Germany). A test pulse in 
control bath solution application (0 ATP) was used to subtract leak currents. Offline analysis 
was performed using Igor Pro-6.37 (WaveMetrics Inc.). Solutions were puffed (~1 second) 
during a 5 second test pulse from a holding potential (Vh) of -70mV. The integer of area 
under the curve described by the inward currents in response to the ATP puff was used for 
quantification of agonist-induced responses, with concentration-response curves plotted as 




Cells on glass coverslips were fixed with 3% paraformaldehyde at 4°C for 15 min then 
washed three times with PBS. Cells were permeabilised with 0.1% saponin in 2% BSA/PBS 
at room temperature for 15 min and then incubated with goat anti-P2X4 (1:250) (Sigma-
Aldrich Cat# SAB2500734, RRID:AB_10604119, Lot# 8830P1) or mouse anti-LAMP1 
(1:100) (DSHB Cat# H4A3, RRID:AB_2296838) antibodies in 2% BSA/PBS  at room 
temperature for two hours. Cells were washed three times with PBS and then incubated with 
Alexa Fluor 594-conjugated donkey anti-goat (1:200) (Abcam Cat# ab150136, 
RRID:AB_2782994, Lot# GR308670-1) or PE-conjugated sheep anti-mouse (1:200) 
(Chemicon Cat# AQ326H, Lot# 985052005) antibodies in 2% BSA/PBS at room temperature 
for 60 minutes. Washed coverslips were mounted onto a glass slide using 50% glycerol in 
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Western blotting 
Cells (1 x 106) were washed three times with ice-cold PBS and harvested by mechanical 
scraping and centrifugation (300 x g for 5 min). Following incubation in complete lysis 
buffer (50 mM BisTris, 750 mM 6-aminohexanoic acid, 1 mM PMSF, 1% n-dodecyl β-D-
maltoside and 1 cOmplete EDTA-free protease inhibitor cocktail tablet, pH 7.0) at 4°C with 
gentle agitation for 60 min, cells were sheared 10 times through an 18 gauge needle and 
centrifuged at 16,000 x g for 15 min at 4°C. Cell supernatants were separated by denaturing 
SDS-PAGE under reducing conditions (10 mM DTT) using Mini-Protean TGX Stain-Free 
gels (4-20%) then transferred onto a nitrocellulose membrane. The membrane was washed 
three times in Tris-buffered saline solution containing Tween-20 (TBST) (20 mM Tris, 500 
mM NaCl, 0.1% Tween-20, pH 7.5) and blocked in blocking buffer (TBST containing 5% 
skim milk powder) for 60 min at room temperature. The membrane was then incubated 
overnight with goat anti-P2X4 (1:500) or rabbit anti-actin (1:2000) (Sigma-Aldrich Cat# 
A2066, RRID:AB_476693) antibodies in blocking buffer at 4°C. The membrane was washed 
three times for 5 min with TBST and incubated with horseradish peroxidase (HRP)-
conjugated mouse anti-goat (Thermo Fisher Scientific Cat# 31400, RRID:AB_228370, Lot# 
KC1205131) or goat anti-rabbit IgG (Rockland Cat# 611-103-122, RRID:AB_218567, Lot# 
21231) (both 1:5000) antibodies in blocking buffer at room temperature for 60 min. The 
membrane was washed as above and visualised using chemiluminescent substrate and an 
Amersham Imager 600RGB (GE Healthcare Lifesciences). The experimental detail for all 
western blots provided conforms with the BJP guidelines (Alexander, Roberts et al., 2018). 
 
Data and statistical analysis 
The relative change in intracellular Ca2+ (ΔCa2+) data was expressed as the ratio of Fura-2 
fluorescence following excitation at 340 nm and 380 nm (F340/380) then normalised to the 
mean basal fluorescence according to the formula ΔCa2+ = ΔF/F = (F − Frest)/Frest, where F is 
the F340/380
 at a given time and Frest is the mean fluorescence of the given well prior to the 
addition of nucleotides (Paredes, Etzler et al., 2008). Nucleotide-induced ΔCa2+ responses 
were then calculated by subtracting the ΔCa2+ response in absence of the respective 
nucleotide (measured simultaneously). To minimise potential caveats of high-throughput 
fluorescence-based assays such as large, erroneous ΔCa2+ measurements (Heusinkveld & 
Westerink, 2011), peak nucleotide-induced ΔCa2+ responses were defined by the median of 
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five readings surrounding the peak nucleotide-induced ΔCa2+ response. To control for plate-
to-plate variation over time and slight variations in P2X4 expression, the peak nucleotide-
induced ΔCa2+ response was normalised to the response to 10 µM ATP alone (percent of 
maximum), which was measured for both canine and human P2X4 for each independent 
experiment. Agonist concentration-response curves were plotted by a non-linear regression fit 
to the Hill equation using the least squares method, following a replicates test to confirm 
adequate fit of the curve. Half-maximal responses are expressed as their negative logarithm 
(pEC50/pIC50) ± SEM. Unpaired two-tailed Student’s t-test or two-way ANOVA with 
Bonferroni post hoc test were used as indicated in the Figure and Table legends where group 
size was equal to at least five independent values (with two or more technical replicates per 
sample to ensure the reliability of single values), there was no significant variance in 
homogeneity (Bartlett’s or F test for equal variance) and the data followed a Gaussian 
distribution (determined by a D'agostino-Pearson omnibus K2 test). Any data with less than 
five independent values were not subject to statistical comparisons. A non-parametric Mann-
Whitney U test was carried out to compare differences when data were normalised to a 100% 
control with no variance. Curve fitting and statistical comparisons were made using 
GraphPad Prism 5 (GraphPad Software, San Diego, CA). Co-localisation analysis and 
calculation of Pearson’s coefficient was performed using the JACoP (Just Another Co-
localization Plugin) tool for ImageJ. Differences between P2RX4 variant prevalence were 
compared using the Fisher’s Exact test. For determining differences between groups, P < 0.05 
was considered statistically significant throughout the entire manuscript and statistical 
analysis was carried out only on independent values, including any outliers. Assays and data 
analysis were performed unblinded and non-randomised, however where possible, plate 
structure was routinely altered to mitigate positioning bias within data sets. The data and 
statistical analysis comply with the recommendations on experimental design and analysis in 
pharmacology (Curtis, Alexander et al., 2018). 
 
Materials, compounds and solutions 
DMEM/F12 medium, ExoSAP-IT, Fura-2 AM, GlutaMAX, HRP-conjugated anti-goat 
antibody, Lipofectamine3000, Opti-MEM I reduced serum medium, penicillin-streptomycin, 
ExoSAP-IT, Subcloning Efficiency™ DH5α™ Competent Cells, TrypLE Express and 
trypsin-EDTA were from Thermo Fisher Scientific (Melbourne, Australia). ABI PRISM 
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BigDye Terminator v3.1 Cycle Sequencing Kit was from Applied Biosystems (Carlsbad, 
USA). MangoTaq DNA polymerase was from Bioline (London, UK). HRP-conjugated anti-
rabbit IgG antibody was from Rockland Immunochemicals (Pottstown, USA). Mini-Protean 
TGX Stain-Free™ gels, Precision Plus Protein™ Dual Colour standards and nitrocellulose 
membrane were from Bio-Rad (Hercules, USA). Alexa Fluor 594-conjugated donkey anti-
goat IgG antibody was from Abcam (Melbourne, Australia). PE-conjugated sheep anti-mouse 
IgG antibody was from Chemicon (Boronia, Australia). Mouse anti-LAMP1 antibody 
(H4A3) was from the Developmental Studies Hybridoma Bank (Iowa City, USA). FBS (heat-
inactivated) was from Bovogen Biologicals (East Keilor, Australia). Wizard Genomic DNA 
Purification and Wizard Plus SV Minipreps DNA Purification kits were from Promega 
(Madison, USA). 6-Aminohexanoic acid, ADP (sodium salt, cat. no. A2754), apyrase (cat. 
no. A6535), ATP (disodium salt, cat. no. A7699), 2’(3’)-O-(4-benzoyl)benzoyl ATP 
(BzATP; triethylammonium salt, cat. no. B6396), cOmplete™ EDTA-free protease inhibitor 
cocktail, n-dodecyl β-D-maltoside, DMSO, (S)-duloxetine (HCl, cat. no. SML0474), EGTA, 
goat anti-P2X4 antibody (SAB2500734), hexokinase from Saccharomyces cerevisae (cat. no. 
H4502), IVM (cat. no. 18898), MEM non-essential amino acid solution, paroxetine (maleate 
salt, cat. no. P1372), PBS, pluronic F-127, PMSF, poly-D-lysine hydrobromide (5 µg.mL-1 
working stock), rabbit anti-actin antibody and saponin were from Sigma-Aldrich (St. Louis, 
USA). 5-(3-Bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one (5-BDBD; 
cat. no. 3579), 1-(2,6-dibromo-4-isopropyl-phenyl)-3-(3-pyriudyl)urea (BX430; cat. no. 
5545), 2’,3’-O-(2,4,6-Trinitrophenyl)-ATP (TNP-ATP; tetra(triethylammonium) salt, cat. no. 
2464) and AR-C118925 (cat. no. 4890) were from Tocris Bioscience (Bristol, UK). BSA, 
EGTA and reagents for preparing buffers were from Sigma-Aldrich or Amresco (Solon, 
USA). Primers for sequencing were obtained from GeneWorks (Hindmarsh, Australia) or 
Integrated DNA Technologies (Coralville, USA). 
Compounds were initially made up to stock concentrations in either Milli-Q H2O (100 mM 
ATP (pH 7.4 with 5 M NaOH), 30 mM ADP, 40 mM BzATP, 10 mM duloxetine and 10 mM 
TNP-ATP) or DMSO (10 mM 5-BDBD, 30 mM BX430, 30 mM paroxetine, 3 mM IVM and 
30 mM AR-C118925). Compounds were stored at -20°C, and then diluted in ECS for Ca2+ 
response assays or standard external solution for patch clamp recordings on the day of use, 
performed unblinded by the experimenter. DMSO controls for each compound (up to 1% in 
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Nomenclature of targets and ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Armstrong, Faccenda et al., 2020), and are permanently 




Genetic characterisation of canine P2X4 
To determine the presence of exonic variants in canine P2RX4, genomic DNA samples from 
a randomly selected cohort of 101 dogs were isolated and sequenced using Sanger 
sequencing. The cohort consisted of 69 pedigree dogs (representing 32 different pedigrees) 
and 32 non-pedigree dogs (Supporting Table 2). Approximately 85% of the protein-coding 
region of P2RX4 for this cohort was sequenced; some regions of various samples could not 
be amplified or sequenced despite three separate attempts. A query of the NCBI dbSNP, the 
EMBL-EBI European Variation Archive (EVA) and the iDOG databases (last accessed 
March 2019) revealed three reported missense variants; one in the first exon of P2RX4 (no 
rsID, 26C>A, A9D; EVA database), one in exon seven (no rsID, 691C>T, R231C; EVA 
database) and one in exon ten (rs852294963, 1033C>G, L345V; NCBI dbSNP database). 
However, these three reported variants were not observed in our cohort, nor were any novel 
missense variants identified (Table 1). Several synonymous variants are also reported in the 
iDOG database (Supporting Table 3), however only rs852444127 (798C>T, T266T) was 
identified in our cohort and then only in heterozygous dosage in two Labrador retrievers and 
one beagle (Table 1). A previously unreported synonymous variant (15C>T) resulting in an 
unchanged cysteine at position five (C5C) was found in our cohort in heterozygous dosage 
only in both pedigree dogs (n = 5) and non-pedigree dogs (n = 3) (Table 1), four of which 
were of Maltese pedigree. This variant was absent in two other Maltese, whilst exon 1 could 
not be amplified in a further four Maltese. Both the allele frequency (0.33 and 0.04) and 
prevalence (66% and 7%) of this variant were significantly different between dogs of Maltese 
and non-Maltese pedigree, respectively. Combined this data indicates that the C5C variant 
may be associated with, but not limited to, dogs of Maltese pedigree. 
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Sequence identity of canine P2X4 
The canine P2X4 amino acid sequence was compared to six cloned P2X4 orthologues (Table 
2). Canine P2X4 had the highest sequence identity (90%) to human P2X4 (Table 2) with the 
highest regions of sequence identity occurring around and within the transmembrane domains 
(Figure 1A). A single M348V substitution exists within the second transmembrane domain of 
canine P2X4, the only difference between the transmembrane domains of canine and human 
P2X4 (Figure 1A). A stretch of 45 amino acids from P176 to A221, which contain a number 
of residues that form the ATP-binding sites of P2X4 (Chataigneau, Lemoine et al., 2013) are 
also conserved between the mammalian species (Figure 1A). P2X4 sequences are relatively 
well conserved between canine and four other mammalian P2X4 orthologues (>85%), but 
this sequence identity drops below 70% (Xenopus) and 60% (zebrafish) when compared to 
taxa outside of the mammalian lineage (Table 2, Figure 1B). 
 
Expression and localisation of cloned canine P2X4 
Human and rodent P2X4 localises primarily to lysosomal compartments (Huang, Zou et al., 
2014; Stokes & Surprenant, 2009). To determine the sub-cellular localisation of canine P2X4, 
1321N1 cells were transfected with canine or human P2X4-EmGFP constructs and analysed 
by confocal microscopy. 1321N1 cells transfected with canine or human P2X4-EmGFP 
revealed a distinct vesicular localisation and to a lesser extent cell-surface expression, both of 
which were similar for canine and human P2X4, visualised either by the EmGFP-tag (Figure 
2A, Supporting Figure 1) or an anti-P2X4 antibody (Supporting Figure 1). In contrast, 
1321N1 cells transfected with the EmGFP empty vector did not display a distinct vesicular 
localisation (cytoplasmic/nuclear distribution) nor were immunolabeled with the anti-P2X4 
antibody at levels above the background fluorescence. Furthermore, both canine and human 
P2X4 appeared to co-localise with lysosomes (Pearson’s coefficient = 0.735 and 0.610, 
respectively) revealed by anti-LAMP1 antibody labelling (Figure 2A). Western blot analysis 
of transfected 1321N1 cells confirmed the presence of a ~80 kDa band corresponding to the 
glycosylated P2X4 -subunit (~55 kDa) plus EmGFP-tag (27 kDa) in transfected, but not 
wild type or EmGFP-transfected 1321N1 cells (Figure 2B), validating the use of this antibody 
for future studies of canine and human P2X4. Similar results were observed for HEK293 
cells transfected with canine or human P2X4-EmGFP constructs (Supporting Figure 2A, B). 
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Pharmacological characterisation of canine P2X4 agonists 
To pharmacologically characterise canine P2X4, the Ca2+ permeability properties of P2X4 
channels were used to measure increases in intracellular Ca2+ bound to the ratiometric, 
fluorescent dye, Fura-2. Incubation with 10 M ATP or 300 M BzATP induced rapid Ca2+ 
responses which peaked within 10-30 seconds of application, followed by a slowly declining, 
sustained period, which was not observed upon addition of ECS vehicle alone (Figure 3A, B). 
Furthermore, these nucleotides evoked peak Ca2+ responses only in 1321N1 cells transfected 
with canine or human P2X4-EmGFP, but not with the EmGFP expression vector alone 
(Figure 3C). 
ATP was the most potent agonist of canine P2X4 (Table 3), evoking a concentration-
dependent Ca2+ response with maximal activity near 10 µM (Figure 3D). ATP produced a 
similar pharmacological profile in 1321N1 cells expressing human P2X4 (Figure 3E). BzATP 
also induced concentration-dependent Ca2+ responses in 1321N1 cells expressing canine and 
human P2X4, although with reduced potency towards canine P2X4 (Figure 3D, E). Peak Ca2+ 
responses achieved with 300 µM BzATP at canine and human P2X4 were 41 ± 7% and 92 ± 
14% of 10 µM ATP, respectively. Unlike ATP, there was a significant difference in EC50 for 
BzATP between canine and human P2X4 (Table 3). Unexpectedly, ADP induced 
concentration-dependent Ca2+ responses in cells expressing canine and human P2X4 (Figure 
3F, G), however, previous studies have reported that commercial stocks of ADP can contain 
small amounts of ATP (Mahaut-Smith, Ennion et al., 2000). Therefore, ADP (and ATP as a 
positive control) was pre-incubated with hexokinase to remove contaminating ATP which 
resulted in significantly reduced ADP-induced Ca2+ responses in canine and human P2X4 
transfected 1321N1 cells (Figure 3F, G). These experiments support previous reports of ATP 
contamination in ADP stocks and suggest that this contaminating ATP may account for the 
unexpected Ca2+ response to ADP. 
To extend these findings, P2X4-mediated Ca2+ response agonist profiles were also 
characterised in HEK293 cells, a commonly used cell line for studying heterologously 
expressed P2X receptors (Jiang & Roger, 2020). Canine and human P2X4-transfected 
HEK293 cells displayed similar Ca2+ response agonist profiles (Figure 4A-D) to those 
observed for transfected 1321N1 cells (ATP pEC50 canine 6.09 ± 0.04, human 6.47 ± 0.03; 
BzATP pEC50 canine < 3, human 4.14 ± 0.06). Furthermore, electrophysiological 
characterisation of canine and human P2X4-mediated responses by automated patch clamp 
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recordings in HEK293 cells was consistent with our Ca2+ response data. Robust inward 
currents were activated with a charge density of 21 ± 7 and 34 ± 16 pC/pF at 100 µM ATP 
for canine and human P2X4, respectively (Figure 4E, F). This resulted in similar ATP 
response profiles in HEK293 cells transfected with canine (pEC50 of 5.02 ± 0.11) and human 
P2X4 (pEC50 5.17 ± 0.10) (Figure 4E-G). No inward currents were elicited by 300 µM ATP 
in patch clamped mock EmGFP-transfected HEK293 cells (Supporting Figure 3A), yet ATP-
induced Ca2+ responses were observed in EmGFP-transfected HEK293 cells (Supporting 
Figure 3B) consistent with the activity of endogenous metabotropic P2Y2 receptors reported 
previously in these cells (Schachter, Sromek et al., 1997). Further investigation of HEK293 
cells transfected with EmGFP vector alone in the absence or presence of 2 mM EGTA (to 
chelate extracellular Ca2+) or 10 µM AR-C118925 (a P2Y2-selective inhibitor) showed that 
the observed ATP-induced Ca2+ response was partially reduced (53 ± 6.4%) in the presence 
of EGTA and almost completely reduced (90.6 ± 5.4%) upon AR-C118925 treatment 
(Supporting Figure 3C). Therefore, further characterisation of Ca2+ responses was limited to 
P2X4-expressing 1321N1 cells. 
  
Ivermectin potentiates ATP-induced Ca2+ flux through canine P2X4 
Ivermectin (IVM) is an allosteric modulator of human and rodent P2X4 (Khakh, Proctor et 
al., 1999; Priel & Silberberg, 2004), but its effect on canine P2X4 is unknown. In order to 
determine if IVM is also a positive allosteric modulator of canine P2X4, cells expressing 
canine or human P2X4 were incubated in the presence or absence of 3 µM IVM (Priel & 
Silberberg, 2004) prior to activation with increasing concentrations of ATP. IVM 
significantly potentiated peak Ca2+ responses observed at 0.1 and 0.3 µM ATP in 1321N1 
cells expressing canine (Figure 5A, B) or human (Figure 5C, D) P2X4, resulting in 2.9- and 
1.7-fold decreases in the ATP EC50 for each orthologue, respectively (Table 3). Consistent 
with these results, ATP-induced inward currents recorded in HEK293 cells expressing canine 
P2X4 were potentiated by 1 µM IVM as demonstrated by a 2.0- to 2.5-fold increase in charge 
density following increased peak inward currents and marked decreases in desensitisation 
kinetics (Supporting Figure 4A, B). The current enhancement observed during our automated 
patch clamp characterisation of canine P2X4-mediated currents supports previous whole-cell 




This article is protected by copyright. All rights reserved. 
Characterisation of canine P2X4 antagonists 
A number of human and rodent P2X4 antagonists have been identified, but no data has been 
published to date regarding their effect on canine P2X4. To address this, Ca2+ responses in 
1321N1 cells transfected with canine P2X4 were assessed using two P2X4-selective 
antagonists (BX430 and 5-BDBD), as well as three non-selective antagonists of human or 
rodent P2X4 (duloxetine, paroxetine and TNP-ATP) (Stokes, Layhadi et al., 2017). At 0.75 
µM ATP (corresponding to the approximate EC80), all five antagonists demonstrated 
concentration-dependent inhibition of both peak and sustained ATP-induced Ca2+ responses 
of canine and human P2X4 (Figure 6A-J). Moreover, with the exception of BX430 and 
paroxetine, each compound displayed similar efficacy against canine and human P2X4 
(Figure 6K-O, Table 3). The P2X4-selective antagonist BX430 was less active against canine 
P2X4 at concentrations greater than 3 µM resulting in a significant reduction in potency 
compared to human P2X4 (Figure 6K, Table 3). In contrast, the non-selective inhibitor 
paroxetine displayed significantly greater potency against canine P2X4 when compared to 
human P2X4 (Figure 6N, Table 3). However, unlike BX430, higher concentrations of 
paroxetine appear to have comparable inhibitory effects at canine and human P2X4. 
Given the similarity in efficacy of the P2X4-selective antagonist 5-BDBD between canine 
and human P2X4 (Figure 6L), and its increasing use in studies of P2X4 activity, the 
mechanism of inhibition of 5-BDBD was further assessed against maximal concentrations of 
P2X4 agonists. 1321N1 cells transfected with canine or human P2X4 were pre-incubated in 
the presence or absence of 30 µM 5-BDBD and then activated with 10 µM ATP or 300 µM 
BzATP. However, despite previously observing inhibition of ATP-induced Ca2+ responses 
with 0.75 µM ATP (~EC80, Figure 6L), 5-BDBD failed to reduce canine or human P2X4 Ca
2+ 
responses evoked by saturating concentrations of 10 µM ATP (Figure 7A). In contrast, 5-
BDBD caused a significant reduction in Ca2+ responses evoked by 300 µM BzATP in cells 
expressing canine or human P2X4 (81 ± 8% and 48 ± 7% reduction, respectively) (Figure 
7B). Taken together, the data presented in Figures 6K and 7A are consistent with 5-BDBD 
being a more potent inhibitor of P2X4 at sub-saturating concentrations of ATP, consistent 
with a competitive mode of inhibition. Accordingly, 300 µM BzATP-induced P2X4 
responses were effectively blocked by 5-BDBD, suggesting that BzATP at this concentration 
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Discussion 
The current study described for the first time, the pharmacology of canine P2X4 and 
indirectly supports the concept that dogs express functional P2X4. Canine P2X4 displayed 
similar in vitro pharmacology to that of human P2X4, with two notable differences: canine 
P2X4 was less sensitive to activation by BzATP and to inhibition by BX430. Our work 
revealed that canine P2X4, like human P2X4, largely resides within intracellular 
compartments that are immunoreactive to LAMP1 consistent with lysosomal localisation. 
Concurrently, we also show that the protein coding region of the P2RX4 gene is highly 
conserved amongst dogs. 
It was determined here that ATP and BzATP are agonists and partial agonists of canine 
P2X4, respectively. Under our experimental setting, the EC50 for ATP was similar for both 
canine and human P2X4, consistent with previously published EC50 values for human, mouse 
and rat P2X4 (Abdelrahman, Namasivayam et al., 2017; Garcia-Guzman, Soto et al., 1997; 
Jones, Chessell et al., 2000; Layhadi, Turner et al., 2018; Soto, Garcia-Guzman et al., 1996). 
Given the high sequence identity between canine and human P2X4 (90%), it was not 
unexpected to identify similar pharmacological profiles towards ATP. This is supported by 
studies demonstrating conservation of crucial ATP-binding residues (underlined in Figure 1) 
across P2X sub-types (Chataigneau, Lemoine et al., 2013; Jiang, Rassendren et al., 2000; 
Roberts, Digby et al., 2008) and amongst human and rodent P2X4 (Abdelrahman, 
Namasivayam et al., 2017). The BzATP EC50 reported here for canine P2X4 is consistent 
with that reported for rat P2X4 (EC50 > 100 µM), but not human or mouse P2X4 
(Abdelrahman, Namasivayam et al., 2017). The data reported here also suggests that BzATP 
is a partial agonist of human P2X4, in agreement with previous studies (Abdelrahman, 
Namasivayam et al., 2017; Bianchi, Lynch et al., 1999; He, Gonzalez-Iglesias et al., 2003). 
The reasons for observed differences in BzATP sensitivity between species are yet to be fully 
understood but may be attributed to variations in BzATP-sensitive residues between species 
leading to less-favourable binding conformations (Browne, Jiang et al., 2010; Pasqualetto, 
Brancale et al., 2018; Tvrdonova, Rokic et al., 2014).  
The current study demonstrated that ADP is not an agonist of canine P2X4 as reported for 
human P2X4 in which 100 µM ADP failed to elicit significant responses (Garcia-Guzman, 
Soto et al., 1997). However, subsequent studies report ADP acting as a P2X4 partial agonist 
(Bianchi, Lynch et al., 1999; Carpenter, Meadows et al., 1999; He, Gonzalez-Iglesias et al., 
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2003). Such discrepancies may be due to the presence of ATP contamination in commercially 
available ADP stocks (Mahaut-Smith, Ennion et al., 2000). Thus, consistent with previous 
studies (Micklewright, Layhadi et al., 2018), ADP was pre-incubated with hexokinase to 
remove any contaminating ATP, which revealed negligible ADP-induced Ca2+ responses in 
1321N1 cells expressing recombinant canine or human P2X4. Thus, as reported by Garcia-
Guzman and colleagues (1997) for human P2X4, ADP does not activate canine P2X4. 
Moreover, caution should be taken when attributing ADP effects on ATP-responsive P2 
receptors when using commercially obtained stocks. 
The current study reported IVM as a positive modulator of canine P2X4. This commonly 
used anti-parasitic drug resulted in significant increases in the efficacy of ATP at canine and 
human P2X4. This increase is consistent with previous reports that IVM positively modulates 
human P2X4 (Priel & Silberberg, 2004). Moreover, the positive modulation of canine P2X4 
by IVM is supported by conservation of critical residues for IVM recognition and binding 
such as Trp46,
 Trp47, Val60 and Val357 (Jelinkova, Yan et al., 2006; Popova, Trudell et al., 
2013). The evidence presented here regarding canine P2X4 sensitivity to IVM, coupled with 
the frequent use of IVM as a preventative treatment for heartworm in dogs, provides a strong 
platform for dogs as natural models of human disease. Recently, IVM has been proposed as a 
potential P2X4-active drug for the treatment of demyelinating diseases like multiple sclerosis 
(Zabala, Vazquez‐Villoldo et al., 2018), however such diseases are seldom reported in 
domestic dogs (Vandevelde & Zurbriggen, 2005). Observations of canine health following 
life-long treatment with IVM could provide valuable insight as to the effect of targeting P2X4 
for treatment or prevention of associated diseases such as multiple sclerosis in humans. 
The current study has shown that three non-selective compounds, duloxetine, paroxetine and 
TNP-ATP, can inhibit canine P2X4. The selective serotonin reuptake inhibitor, paroxetine, 
and the serotonin-norepinephrine reuptake inhibitor, duloxetine, are reported to non-
selectively inhibit human and rodent P2X4 (Nagata, Imai et al., 2009; Yamashita, Yamamoto 
et al., 2016), as well as to alleviate allodynia in models of chronic pain (Iyengar, Webster et 
al., 2004; Zarei, Sabetkasaei et al., 2014). Consistent with these previous studies, both 
compounds demonstrated effective inhibition of canine and human P2X4, albeit at relatively 
high concentrations (>100 µM). Moreover, the broad-spectrum P2X receptor antagonist 
TNP-ATP blocked canine and human P2X4 with similar potency, which agrees with previous 
work describing TNP-ATP as an antagonist of human and rodent P2X4 (Abdelrahman, 
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Namasivayam et al., 2017; Nagata, Imai et al., 2009). These compounds lack selectivity for 
P2X4 and as such, their use for studying canine P2X4 may be limited. However, given that 
duloxetine and paroxetine are approved human drugs, they may provide potential therapeutic 
benefits in dogs, in which P2X4 may be implicated. 
This study also demonstrated that two selective inhibitors of P2X4, BX430 and 5-BDBD, can 
inhibit canine P2X4. The data presented here identified the phenylurea BX430 as a 
moderately potent antagonist of canine P2X4, although with a four-fold higher IC50 than for 
human P2X4. This is consistent with species differences reported with BX430 where this 
compound has displayed potent inhibition of human and bovine P2X4, moderate inhibition of 
zebrafish and Xenopus P2X4, and no inhibition of rodent P2X4 (Ase, Honson et al., 2015; 
Ase, Therrien et al., 2019). Ase and colleagues (2019) have attributed this difference to a 
single P2X4 residue (Ile312 human numbering, highlighted green in Figure 1A) which forms 
a docking site with Asp88 and Tyr300 and plays a crucial role in determining sensitivity to 
BX430. The conservation of this docking site between P2X4 orthologues such as canine, 
human and zebrafish and the apparent differences in sensitivity to BX430 may indicate a role 
for additional residues in mediating the inhibitory effects of BX430. 
In contrast, the benzodiazepine derivative 5-BDBD inhibited canine and human P2X4 with 
similar potency but with limited effectiveness compared to other inhibitors. Consistent with 
this data, 5-BDBD has been reported as a moderately potent inhibitor of human and rodent 
recombinant P2X4, with limited effectiveness at sub-micromolar concentrations 
(Abdelrahman, Namasivayam et al., 2017; Ase, Honson et al., 2015; Balazs, Danko et al., 
2013; Coddou, Sandoval et al., 2019). The data presented here is also in agreement with 
recent studies demonstrating inhibition of endogenous P2X4 activity in human monocyte-
derived macrophages (Layhadi & Fountain, 2017) and human CD4+ T cells (Ledderose, Liu 
et al., 2018). Furthermore, the current study reported 5-BDBD to be ineffective at inhibiting 
Ca2+ responses induced by saturating concentrations of ATP. This is consistent with reports 
describing 5-BDBD as a competitive inhibitor of P2X4 assessed by radioligand binding 
assays (Balazs, Danko et al., 2013) suggesting that this compound may have an allosteric 
inhibitory mechanism (Abdelrahman, Namasivayam et al., 2017). Nonetheless, the limited 
potency and efficacy of BX430 and 5-BDBD highlights the need to identify more potent, 
selective P2X4 antagonists for treating disease in humans and dogs. 
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The current study also demonstrated that canine P2X4, like human and rodent P2X4, is 
predominantly localised to intracellular compartments of cells, with limited expression at the 
plasma membrane. Consistent with what has previously been shown for human and rodent 
P2X4 (Huang, Zou et al., 2014; Stokes & Surprenant, 2009), canine P2X4 co-localised with 
LAMP1-labelled lysosomes. This data is further supported by observations that di-leucine 
(L22I23) and tyrosine-based (Y372xxV and Y378xxGL) endo-lysosomal targeting motifs 
(Qureshi, Paramasivam et al., 2007) are conserved in canine P2X4. Moreover, expression of 
functional canine P2X4 on lysosomal compartments supports growing evidence for a 
physiological role of P2X4 in lysosomal membrane trafficking and fusion (Murrell-Lagnado 
& Frick, 2019). In addition, despite transfection with equal amounts of plasmid DNA, the 
Ca2+ response and current magnitude for human P2X4 were repeatedly higher than those for 
canine P2X4. This difference likely reflects differences in transcription and translation rates 
of canine and human P2X4, or the expression of a canine protein in a human cell line. 
Notably, uncharacterised effects on ion channel physiology and/or pharmacology arising 
from attachment of EmGFP to the C-terminal of P2X4 cannot be discarded despite 
representing a common approach utilised in functional characterisation (Sadovnick, Gu et al., 
2017). 
The current study determined that the coding sequence of P2RX4 is highly conserved 
amongst 101 dogs. The lack of genetic variation in canine P2RX4 contrasts that of canine 
P2RX7 (Sophocleous, Sluyter et al., 2019; Spildrejorde, Bartlett et al., 2014) which encodes 
four characterised missense variants. The difference between canine P2RX4 and P2RX7 
parallels the frequencies of missense variants between human P2RX4 (Stokes, Scurrah et al., 
2011) and P2RX7 (Stokes, Fuller et al., 2010). Since the publication of the canine genome 
(Lindblad-Toh, Wade et al., 2005), few missense P2RX4 variants have been reported in 
canine genome databases (dbSNP, EVA, iDOG,), however none so far have been validated 
by publication or characterised in functional studies. Nonetheless, the reduced polymorphic 
variation in canine P2RX4 compared to human P2RX4 is consistent with current observations 
of genome-wide loss in genetic variation due to domestication and selective breeding 
(Ostrander, Wayne et al., 2017). Currently, there are around 400 recognised domestic 
pedigrees worldwide (Ostrander, Wayne et al., 2017). With such a diverse range of pedigrees 
worldwide, there is potential for regional or pedigree bias within the present study, with 
Labrador, Staffordshire and Maltese associated pedigrees collectively forming over one third 
of the total cohort. Just over one quarter of the pedigrees in this cohort are represented by a 
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single sample and as such, the identification of P2RX4 variants may have been precluded, 
particularly if they exhibit a very low minor allele frequency or are more commonly 
associated with particular pedigrees. 
The unique establishment of dogs as close human companions and the high level of sequence 
identity between the two species has resulted in the recognition of dogs as natural models of 
human ageing and disease (Sandor & Kubinyi, 2019). This, in part, can be attributed to 
breeding programs and implementation of veterinary medicine, resulting in aged canine 
populations, and with this, diseases that are prevalent in aged human populations like chronic 
pain, inflammation, and neurodegenerative diseases. P2X4 has known roles in controlling 
inflammation, chronic pain, remyelination and pulse pressure in humans and rodents 
(Bernier, Ase et al., 2018; Stokes, Scurrah et al., 2011; Su, Wu et al., 2019; Zabala, Vazquez‐
Villoldo et al., 2018). The current functional characterisation of canine P2X4 suggests 
potential roles in canine physiology and disease. However, expression of P2X4 in canine 
tissues is limited to P2X4 transcripts reported in brain and gastrointestinal tissue from dogs 
(Lee, Ro et al., 2005) and P2X4 protein detected in dog arteries (Delorey, Clifford et al., 
2012). Thus, future studies would benefit from utilising known P2X4 expression patterns in 
human and rodent tissues such as blood vessels, brain, gut, lungs and immune cells 
(Burnstock & Knight, 2004), to aid in identifying canine tissues that express P2X4. 
P2X4 is an important signalling molecule with potential for therapeutic targeting for the 
treatment of major health issues including chronic pain, nerve damage and cardiovascular 
disease. The data presented here will aid the development of more potent and selective P2X4-
targetting compounds, and will assist with pre-clinical validation of potential therapeutics for 
P2X4-related diseases in both human and veterinary medicine. 
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Table 1. Distribution of canine P2RX4 exon variants in our cohort of dog samples. 
 











Observed variantsb       
C5C tgC>tgT 15 63 55 8 0.063 12.7% 
T266T acC>acT 798 88 85 3 0.017 3.4% 
Reported variantsc       
A9D gcC>gcA 26 63 55 0 ND ND 
R231C Cgt>Tgt 691 90 90 0 ND ND 
L345V Ctc>Gtc 1033 82 82 0 ND ND 
aOnly heterozygous variants were observed in this cohort 
bVariants that were observed at least once in our cohort 
cVariants reported previously in either dbSNP, EVA or iDOG databases but not observed in this study 
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Table 2. Sequence identity between protein sequences of cloned P2X4 orthologues. 
 
 
 Sequence identity (%) 
Caninea Humanb  Bovinec Moused  Rate Xenopusf Zebrafishg 
Canine 100 90 88.7 86.1 85.6 69.5 56.5 
Human  100 87.4 86.9 87.4 69.7 58.3 
Bovine   100 85.6 85.8 68.2 56.5 
Mouse    100 95.6 67.7 57.8 
Rat     100 68.2 59.1 
Xenopus      100 56.6 
Zebrafish       100 
Sequences were obtained from the NCBI protein database with the exception of the full length canine P2X4 
sequence which was unavailable from NCBI and was retrieved from ENSEMBL. Sequences were aligned with 
Clustal O (v1.2.4) and sequence identity determined using the percent identity matrix tool.  
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Table 3. Pharmacological activity of compounds mediating changes in intracellular Ca2+ in 
1321N1 cells expressing canine or human P2X4. 
 
 
Canine P2X4 Human P2X4 
pEC50 or pIC50 
Hill 
coefficient 
pEC50 or pIC50 
Hill 
coefficient 
Agonists (pEC50)a      
ATP 6.59 ± 0.13 1.89 6.72 ± 0.06 1.59 
BzATP 3.44 ± 0.13*† (41%) 1.72 5.04 ± 0.26† (92%) 1.68 
ADPb N.R (<10%) - N.R. (<10%) - 
Modulators (pEC50)c     
IVM 6.98 ± 0.05† (111%) 1.60 6.91 ± 0.13† (137%) 1.85 
ATP 6.52 ± 0.12 2.09 6.69 ± 0.07 1.66 
Antagonists (pIC50)d     
BX 430 5.11 ± 0.06* (43%) 1.65 5.71 ± 0.08 (29%) 1.29 
5-BDBD 5.24 ± 0.24 (53%) 0.89 5.28 ± 0.36 (54%) 0.99 
Duloxetine 4.82 ± 0.20 (13%) 1.00 4.77 ± 0.18 (13%) 1.00 
Paroxetine 4.88 ± 0.13* (28%) 0.76 4.11 ± 0.20 (37%) 0.84 
TNP-ATP 5.09 ± 0.27 (18%) 1.00 5.36 ± 0.24 (8%) 1.00 
aValues in parentheses indicate the percent of max response compared to 10 µM ATP. 
bADP in the presence of hexokinase to remove contaminating ATP. 
cpEC50 of ATP in the absence or presence of 3 µM IVM; values in parentheses indicate the percent of response 
compared to 10 µM ATP. 
dpIC50 of antagonists calculated using the approximate pEC80 of ATP (0.75 µM); values in parentheses indicate 
the percent of response in the presence of 100 µM antagonist compared to max ATP in absence of antagonist. 
N.R. negligible response (pEC50 not calculated). *P < 0.05 compared to the pEC50 or pIC50 of respective 
compound at human P2X4; †P < 0.05 compared to ATP alone for corresponding P2X4 (non-parametric Mann-
Whitney U test for agonists and IVM, parametric Student’s t-test for antagonists). Data are mean ± SEM from 
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Figure 1. Multiple sequence alignment of known mammalian P2X4 receptors. (A) P2X4 
sequences were aligned using Clustal O v1.2.4 (https://www.ebi.ac.uk/Tools/msa/clustalo/; 
last accessed November 2019). Asterisks (*) underneath the alignment indicate residues that 
are identical between all five orthologues and blank spaces indicate where differences are 
observed. Sections highlighted grey indicate where canine and human residues are identical 
but differ compared to other non-human orthologues, and sections highlighted blue indicate 
where canine and human residues differ. Predicted transmembrane domains based on the 
Expasy TMpred prediction program (https://www.expasy.org/; last accessed November 2019) 
are highlighted yellow. The amino acid residue involved in P2X4 orthologue sensitivity to the 
P2X4 antagonist BX430 (identified by Ase, Therrien et al. (2019)) is highlighted green. 
Residues where two of the above occur are indicated by dual-highlighted split boxes. Amino 
acids involved in ATP binding are underlined. Dog (dP2X4; P2RX4-201 
ENSCAFT00000013312.3), human (hP2X4; NP_002551.2), bovine (bP2X4; 
NP_001029221.1), mouse (mP2X4; NP_035156.2) and rat (rP2X4; NP_113782.1) P2X4 
protein sequence entries were obtained from ENSEMBL or NCBI (last accessed November 
2019). (B) Phylogenetic tree calculated from Clustal O multiple sequence alignment of above 
P2X4 sequences, as well as zebrafish P2X4 (NP_705939.1) and Xenopus P2X4 
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Figure 2. Expression of canine and human P2X4 in 1321N1 cells. (A) 1321N1 cells, 
transfected with canine or human P2X4-EmGFP, or EmGFP vector alone, were fixed, 
permeabilised and stained with anti-LAMP1 antibody to label lysosomes. Cells were imaged 
by confocal microscopy and co-localisation analysed using ImageJ. Inset squares were 
digitally enlarged three times the original to examine P2X4 localisation in vesicular 
compartments. Scale bar = 20 µm. (B) Proteins of whole cell lysates of non-transfected 
1321N1 cells (Nil) and 1321N1 transfected with canine (cP2X4) or human (hP2X4) P2X4-
EmGFP or EmGFP vector alone (EmGFP) were examined by western blotting using an anti-





This article is protected by copyright. All rights reserved. 
 
Figure 3. Ca2+ response agonist profile of canine and human P2X4 in 1321N1 cells. (A-G) 
1321N1 cells, transfected with canine or human P2X4-EmGFP or EmGFP (control) plasmid 
DNA, were loaded with Fura-2 and incubated in the absence or presence of each nucleotide 
in ECS (as indicated). (A, B) Representative ΔCa2+ traces for each nucleotide at respective 
maximal concentration. Solid and dashed lines indicate Ca2+ traces in presence or absence of 
nucleotide, respectively. (C) Peak ΔCa2+ response to maximal concentrations of ATP (10 
µM) and BzATP (300 µM). (D-G) Nucleotide-induced ΔCa2+ responses are presented as 
percent of maximum response to 10 µM ATP, with data fit to the Hill equation to produce 
concentration-response curves. (F, G) ADP or ATP were pre-incubated with hexokinase (4.5 
U.mL-1) for 1 hour at 37°C prior to addition. Red open and closed circles represent 10 µM 
ATP in the presence or absence of hexokinase, respectively. (A-H) Data shown are mean ± 
SEM from five independent experiments (or eight for ATP concentration-response curve). *P 
< 0.05 compared to nucleotide in absence of hexokinase using a two-way ANOVA with 
Bonferroni post hoc test following a D’agostino-Pearson test for normality. 
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Figure 4. Agonist profile of canine and human P2X4 in HEK293 cells. (A-G) HEK293 cells, 
transfected with canine or human P2X4-EmGFP plasmid DNA. (A-D) Cells were loaded 
with Fura-2 and incubated in the absence or presence of each nucleotide (as indicated). (A, B) 
Representative ΔCa2+ traces for each nucleotide at respective maximal concentration. Solid 
and dashed lines indicate Ca2+ traces in presence or absence of nucleotide in ECS, 
respectively. (C, D) Nucleotide-induced ΔCa2+ responses are presented as percent of 
maximum response to 10 µM ATP. Data shown are mean ± SEM from five independent 
experiments. (E, F) Representative automated whole-cell patch clamp current traces of canine 
or human P2X4 in absence or presence of increasing concentrations of ATP (as indicated by 
the bars above the current traces) in standard external solution. (G) ATP-induced inward 
currents are presented as charge density (pC/pF) normalised to current at 1 mM ATP, with 
data fit to the Hill equation to produce concentration-response curves. Data shown are mean 
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Figure 5. Modulation of ATP-induced Ca2+ responses by ivermectin (IVM) on canine and 
human P2X4 in 1321N1 cells. (A-D) 1321N1 cells, transfected with canine or human P2X4-
EmGFP, were loaded with Fura-2 and pre-incubated in the absence (vehicle, 0.1% DMSO in 
ECS) or presence of 3 µM IVM for 20 minutes. Cells were incubated in the absence or 
presence of increasing concentrations of ATP. (A, C) Representative ΔCa2+ traces for 0.3 µM 
ATP, where solid and dashed lines indicate Ca2+ traces in absence or presence of IVM, 
respectively. (B, D) ATP-induced ΔCa2+ responses are presented as percent of maximum 
response to 10 µM ATP in the absence of IVM, with data fit to the Hill equation to produce 
concentration-response curves. (A-D) Data shown are mean ± SEM from five independent 
experiments. *P < 0.05 compared to respective ATP concentration in absence of IVM using a 
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Figure 6. Ca2+ response antagonist profiles of canine and human P2X4 in 1321N1 cells. (A-
O) 1321N1 cells, transfected with canine or human P2X4-EmGFP, were loaded with Fura-2 
and incubated in the absence (ECS alone or 1% DMSO in ECS) or presence of increasing 
concentrations of BX430 (1% DMSO), 5-BDBD (1% DMSO), duloxetine (ECS), paroxetine 
(1% DMSO) or TNP-ATP (ECS) for 20 minutes and then exposed to 0.75 µM ATP 
(approximate to the EC80 of ATP). Representative ΔCa
2+ traces in absence or presence of 
antagonists at (A-E) canine and (F-J) human P2X4. (K-O) ATP-induced ΔCa2+ responses are 
presented as percent of maximum response to 10 µM ATP in the absence of antagonists, with 
data fit to the Hill equation to produce concentration-response curves. Data points indicate 
the mean ± SEM from five independent experiments. 
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Figure 7. Inhibitory effect of 5-BDBD at maximal P2X4 agonist concentrations. (A, B) 
1321N1 cells, transfected with canine or human P2X4-EmGFP, were loaded with Fura-2, 
pre-incubated in the absence (0.3% DMSO in ECS) or presence of 30 µM 5-BDBD for 20 
minutes and then incubated with maximal or near maximal concentrations of (A) ATP or (B) 
BzATP, respectively. Data were plotted as a percentage of the maximal response to 10 µM 
ATP in absence of antagonist. Data are presented as the mean ± SEM from six independent 
experiments. *P < 0.05 compared to nucleotide alone using a parametric Student’s t-test. 
 
